Innovative Tools for Immunotherapy Research

Immunotherapy has shown tremendous promise in treating various types of cancer. BPS Bioscience has pioneered novel research tools, including recombinant proteins, bispecific and trispecific antibodies, lentiviruses, recombinant cell lines, and assay kits to further advance discoveries in immunotherapy.  Focused on the areas of immune checkpoint blockade, CAR-T cells, CAR-NK cells, cytokines, and more, they provide an extensive selection of quality products, as well as screening and profiling services.

Their quality cell-based assay kits, such as the PD-1:PD-L1 Cell-Based Inhibitor Screening Assay Kit, provide sensitive detection systems to measure immune modulation of cell-to-cell protein interactions.

cell-based inhibitor screening assay kit

Their CRISPR/Cas9 lentiviruses are quality tested to verify knockdown expression of target proteins, such as CTLA4, TIGIT, PD-1, PD-L1, LAG3, TCR and more.  They also provide lentiviruses carrying target-specific CAR constructs to induce expression in target cells.

Jurkat cells were transduced via spinoculation with 5,000,000 TU/well of TCR CRISPR/Cas9 lentivirus. 72 hours after transduction, cells were stained with PE anti-human TCR antibody and analyzed by FACS. Parental Jurkat cells are shown in blue, and the transduced cells are shown in green.


Discover the BPS Bioscience portfolio